A detailed history of Federated Hermes, Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 87,425 shares of RLMD stock, worth $241,292. This represents 0.0% of its overall portfolio holdings.

Number of Shares
87,425
Previous 96,010 8.94%
Holding current value
$241,292
Previous $288,000 1.74%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.3 - $4.36 $19,745 - $37,430
-8,585 Reduced 8.94%
87,425 $283,000
Q1 2024

May 14, 2024

SELL
$3.1 - $6.8 $11,869 - $26,037
-3,829 Reduced 3.84%
96,010 $446,000
Q4 2023

Jan 31, 2024

SELL
$2.45 - $4.22 $35,189 - $60,611
-14,363 Reduced 12.58%
99,839 $413,000
Q3 2023

Nov 13, 2023

BUY
$2.48 - $3.79 $193 - $295
78 Added 0.07%
114,202 $342,000
Q2 2023

Aug 14, 2023

BUY
$2.22 - $3.54 $253,355 - $403,998
114,124 New
114,124 $280,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $79M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.